Cite
Lues I, Weber F, Meyer A, et al. A phase 1 study to evaluate the safety and pharmacokinetics of PQ912, a glutaminyl cyclase inhibitor, in healthy subjects. Alzheimers Dement (N Y). 2015;1(3):182-195doi: 10.1016/j.trci.2015.08.002.
Lues, I., Weber, F., Meyer, A., Bühring, U., Hoffmann, T., Kühn-Wache, K., Manhart, S., Heiser, U., Pokorny, R., Chiesa, J., & Glund, K. (2015). A phase 1 study to evaluate the safety and pharmacokinetics of PQ912, a glutaminyl cyclase inhibitor, in healthy subjects. Alzheimer's & dementia (New York, N. Y.), 1(3), 182-195. https://doi.org/10.1016/j.trci.2015.08.002
Lues, Inge, et al. "A phase 1 study to evaluate the safety and pharmacokinetics of PQ912, a glutaminyl cyclase inhibitor, in healthy subjects." Alzheimer's & dementia (New York, N. Y.) vol. 1,3 (2015): 182-195. doi: https://doi.org/10.1016/j.trci.2015.08.002
Lues I, Weber F, Meyer A, Bühring U, Hoffmann T, Kühn-Wache K, Manhart S, Heiser U, Pokorny R, Chiesa J, Glund K. A phase 1 study to evaluate the safety and pharmacokinetics of PQ912, a glutaminyl cyclase inhibitor, in healthy subjects. Alzheimers Dement (N Y). 2015 Oct 03;1(3):182-195. doi: 10.1016/j.trci.2015.08.002. eCollection 2015 Nov. PMID: 29854937; PMCID: PMC5975062.
Copy
Download .nbib